Urge Roche to lower the cost of its breast cancer drug Kadcyla.

Kadcyla has been approved in the E.U. for advanced HER2-positive breast cancer extending patients lives by a median of six months in clinical studies. 

Roche's website states that:  "Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients"  however at £90,000 cost per patient NICE have been unable to approve it for NHS use. 

Please sign this petition, urging Roche to lower their price so that they can achieve their own heathcare strategy aims and allow the people this drug has been made for to be able to benefit from it.